S.B. No. 3005 is a bill that mandates the Texas Department of State Health Services to conduct a comprehensive study on the use of psychedelic therapies, specifically MDMA, psilocybin, and ketamine, for treating mental health conditions such as post-traumatic stress disorder (PTSD) and depression. The study will involve collaboration with Baylor College of Medicine and the Center for Psychedelic Research and Therapy at Dell Medical School. The department is tasked with reviewing clinical trials, current literature, and FDA actions related to these therapies, as well as evaluating treatment guidelines and patient access to ensure that once approved, these therapies are accessible to those in need.

The bill requires the department to submit a written report by December 1, 2026, detailing the study's findings and any recommendations for legislative or other actions to facilitate patient access to psychedelic therapies post-FDA approval. The act is set to expire on September 1, 2027, and will take effect on September 1, 2025.